Table 1.
Clinical characteristics of patients at admission.
| Clinical characteristics | n | n (%/Mean ± SDa) |
|---|---|---|
| Age (y) | 168 | 9.87 ± 3.67 |
| Gender (female) | 168 | 81 (48.21%) |
| VTE occurrences | 168 | 63 (37.5%) |
| Anticoagulation therapy | 108 | 16 (14.81%) |
| Tumor volume (cm2) | 119 | 28.47 ± 9.27 |
| Tumor gradeb | 168 | |
| 3 | 91 (54.17%) | |
| 4 | 77 (45.83%) | |
| Gene expression | 121 | |
| IDH1 MUT | 20 (16.53%) | |
| ATRX+ | 8 (6.61%) | |
| EGFR+ | 29 (23.97%) | |
| MGMT methylation | 39 (32.23%) | |
| p53 MUT | 23 (19.01%) | |
| Treatment | 147 | |
| Radiotherapy | 119 (80.95%) | |
| Chemotherapy | 59 (40.69%) | |
| Target therapies | 12 (8.16%) | |
| Chinese traditional medicine | 11 (7.48%) | |
| Prolonged bed restc | 113 | 105 (92.92%) |
| Glucocorticoid therapy | 152 | 64 (42.11%) |
| History of CVCP | 146 | 12(8.22%) |
VTE, venous thromboembolism; IDH1 MUT, isocitrate dehydrogenase 1 mutation; ATRX +, alpha-thalassemia/mental retardation syndrome X-linked positive; EGFR +, epidermal growth factor receptor positive; MGMT, O6-methylguanine-DNA methyltransferase; p53, tumor protein p53; CVCP, central venous catheter placement.
a
Categorical variables are presented as percentages, while continuous variables are presented as mean ± standard deviation.
b
According to the retained pathological reports.
c
Bed rest for more than 2 weeks.